[DOI] [PubMed] [Google Scholar] 49.Tobaiqy M., Elkout H
Supplementary Information The online version of this article ( contains peer-reviewed but unedited supplementary material
Among patients with type 2 diabetes (T2D), the risk of CVD is substantially elevated ( Glucagon-like pepetide-1 GLP-1 is an incretine hormone that has a pivotal role in metabolic processes
36 The next frontier: Quality weight loss The current generation of GLP-1s is fantastic at dropping weight, but a strategic vulnerability is muscle wasting. Up to 25-40% of the weight lost on these drugs can be lean muscle mass
Interestingly enough, patients with higher baseline ASCVD risk with tirzepatide therapy showed significantly more reductions in risk [3]
GLP-1 agonists (semaglutide, dulaglutide, liraglutide) slow gastric emptying as part of their mechanism to control blood glucose and reduce appetite